BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
10.31
-0.11 (-1.06%)
Mar 9, 2026, 4:00 PM EDT - Market closed

BBOT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Net Income
-134.04-74.28-64.7
Depreciation & Amortization
0.610.210.09
Loss (Gain) From Sale of Investments
-1.26-1.54-
Stock-Based Compensation
5.874.4316.47
Other Operating Activities
8.490.56-
Change in Accounts Payable
-1.842.50.27
Change in Other Net Operating Assets
8.2713.1-4.2
Operating Cash Flow
-113.89-55.03-52.08
Capital Expenditures
-0.61-0.05-0.41
Investment in Securities
73.93-122.89-
Other Investing Activities
-2.41-2.41
Investing Cash Flow
73.33-120.53-2.82
Issuance of Common Stock
373.51.113.62
Other Financing Activities
-12.32--
Financing Cash Flow
383.4206.2955.12
Net Cash Flow
342.8430.730.23
Free Cash Flow
-114.5-55.08-52.49
Free Cash Flow Per Share
-3.68-4268.47-420.87
Levered Free Cash Flow
-74.19-42.53-
Unlevered Free Cash Flow
-74.19-42.53-
Change in Working Capital
6.4315.59-3.94
Source: S&P Capital IQ. Standard template. Financial Sources.